Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Chardan Capital Maintains Buy on Homology Medicines, Lowers Price Target to $8

Chardan Capital analyst Matthew Barcus maintains Homology Medicines (NASDAQ:FIXX) with a Buy and lowers the price target from $10 to $8.
byBenzinga Newsdesk
November 17, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Chardan Capital analyst Matthew Barcus maintains Homology Medicines (NASDAQ:FIXX) with a Buy and lowers the price target from $10 to $8.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts